Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical

Purpose In this clinical trial, we evaluated Alpha (R) ointment efficacy in prevention of capecitabine induced hand-foot syndrome (HFS) in patients with gastrointestinal or breast cancers, for the first time. Methods During this pilot, randomized, triple-blinded, placebo-controlled clinical trial, the effect of Alpha (R) ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/30 g) was assessed. It was applied on the palms and the soles, two times daily starting at the first day of chemotherapy for 4 consecutive courses. The severity of HFS was assessed at the end of the chemotherapy courses based on World Health Organization (WHO) scale and scored between 0-4. Results Ninety eligible patients were included randomly in the treatment or placebo group. Median WHO HFS grade was not significantly different between the two groups, during the follow-up period (P > 0.05). In the weekly assessment, the scores increased meaningfully in both the placebo and treatment groups, but there was a delay in HFS occurrence and deterioration in Alpha ointment group based on post hoc analysis. Conclusion Administration of Alpha (R) ointment containing henna and curcumin could not significantly prevent capecitabine induced HFS during 4 courses of treatment, but can somewhat delay its occurrence in patients with gastrointestinal or breast cancer.

Automated summary

This study evaluated the efficacy of Alpha (R) ointment in preventing capecitabine induced hand-foot syndrome in patients with gastrointestinal or breast cancers. The results showed that Alpha (R) ointment did not significantly prevent the occurrence of HFS, but it can somewhat delay its onset.